COMMUNIQUÉS West-GlobeNewswire

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
24/07/2025
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading [...]
The Joint Corp. to Host Conference Call on Thursday, August 7th to Discuss Second Quarter 2025 Results
24/07/2025
SCOTTSDALE, Ariz., July 24, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, announced it will report its second [...]
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
24/07/2025
– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy – MELBOURNE, [...]
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
24/07/2025
TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which [...]
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
24/07/2025
-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients [...]
Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
24/07/2025
Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, development and commercial milestones Matchpoint will [...]
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, [...]
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
24/07/2025
KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune [...]
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
24/07/2025
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
24/07/2025
Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging CARSON CITY, Nev., July 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“ [...]
Citryll Announces Formation of Scientific Advisory Board
24/07/2025
CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD Board comprises world-renowned experts in biology, immunology and pathology Oss, Netherlands – 24 July 2025 – Citryll, a biotech company pioneering a [...]
First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2
24/07/2025
Group net sales grow by 6.3%* to EUR 14.0 billion, driven by Human Pharma (EUR 11.3 billion) and Animal Health (EUR 2.6 billion) Regulatory submissions underway for zongertinib and nerandomilast, with launches expected [...]
Communiqué de presse : Efluelda®, le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026
24/07/2025
Efluelda ® , le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026 Paris, le 24 juillet 2025 – Sanofi annonce la mise à disposition en France d'Efluelda, son vaccin haute [...]
Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients
24/07/2025
Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/ [...]
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
24/07/2025
July 24, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
24/07/2025
Basel, 24 July 2025 Group sales grew by 7% 1 at constant exchange rates (CER; 4% in CHF), driven by strong demand for medicines. Pharmaceuticals Division sales rose by 10% (6% in CHF), with Phesgo (breast cancer), [...]
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
24/07/2025
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a [...]
AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’étude confirmatoire de phase 3 avec le masitinib dans la SLA
24/07/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE A OBTENU L'AUTORISATION DE PLUSIEURS PAYS EUROPÉENS POUR INITIER L’ETUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE CETTE AUTORISATION FAIT SUITE A [...]
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
24/07/2025
PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL VALIDATION BY THE [...]

Pages